Trump pledges support for Alzheimer’s disease research

As November marks National Alzheimer’s Disease Awareness Month, the White House released a statement expressing commitment to cutting-edge research in Alzheimer’s disease.

“For these Americans struggling with the disease as it gradually erodes their ability to think, learn, and remember, we must all do our best to alleviate suffering, open our hearts, and provide loving care. Additionally, our institutions must pursue research and other opportunities to help eradicate the disease in the future. We can and must do better,” the statement read. “This month, we also acknowledge the millions of caregivers currently assisting those with a diagnosis of dementia. They know firsthand that the cost of such a diagnosis is measured not just in dollars and cents, but also in the emotional and physical effort required to help loved ones.”

Alzheimer’s disease is the sixth leading cause of death in the U.S., according to the statement.

Approximately 5.3 million Americans aged 65 years and older have Alzheimer’s disease, and an estimated 14 million Americans may develop the disease by 2050.

To commemorate the national observance and highlight the importance of research in Alzheimer’s disease, Healio.com/Psychiatry gathered the most popular articles on the topic.

New approach may determine dementia risk in patients with MCI

Recent findings showed accuracy of biomarker-based prognostic models for determining Alzheimer’s disease dementia and any type of dementia among patients with mild cognitive impairment. Read more

Methylphenidate improves apathy in mild Alzheimer’s disease

Methylphenidate significantly improved apathy, cognition, functional status, caregiver burden and depression among community-dwelling veterans with mild Alzheimer’s disease. Read more

Personality changes do not begin before Alzheimer’s disease onset

Changes in personality, specifically neuroticism, conscientiousness and extraversion, did not begin before the onset of mild cognitive impairment or Alzheimer’s disease, according to recent findings. Read more

Digital SAGE assessment accurate for early dementia

Data presented at the Alzheimer’s Association International Conference indicated efficacy of a digital version of the Self-Administered Gerocognitive Examination, a brief cognitive assessment for mild cognitive impairment and early dementia. Read more

Rexulti improves agitation in Alzheimer's disease

Findings from two phase 3 clinical trials indicated efficacy, safety and tolerability of Rexulti for agitation in individuals with Alzheimer’s disease. Read more